22. Okt. 2018Alison Birtle, MD

ESMO 2018: We have effective therapies – now we need to find their right sequence

Alison Birtle, MD, of Royal Preston Hospital Lancashire Teaching Hospitals, Preston, UK, shares her insights on ESMO’s developments in prostate cancer.

Chi KN et al., A Randomized Phase 2 Study of Cabazitaxel (CAB) vs (ABI) Abiraterone or (ENZ) Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer (mCRPC). Abstract #792O

Fizazi K et al., Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. Abstract #791O

Smith MR et al., ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Abstract # LBA30

Parker CC et al., Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476). Abstract #LBA5_PR

De Wit R et al., Pembrolizumab for High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial. Abstract #864O

Petrylak I et al., RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. Abstract # 865PD